Jiangsu Hengrui Pharmaceuticals (600276) Stock Price, News, Quotes-Moomoo

CN Stock MarketDetailed Quotes

600276 Jiangsu Hengrui Pharmaceuticals

Watchlist

42.84
-0.06-0.14%

Market Closed Jan 17 15:00 CST

273.28BMarket Cap50.16P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Jiangsu Hengrui Medicine Gets Approval to Conduct Clinical Trials for Two Anti-tumor Drugs
MT NewswiresJan 17 00:34 ET
Express News | Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Report Positive Topline Data From 8 Mg Dose of Phase 2 Obesity Trial of GLP-1/Gip Receptor Dual Agonist Hrs9531
ReutersJan 13 08:00 ET
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Report Positive Topline Data From 8 Mg Dose of Phase 2 Obesity Trial of GLP-1/GIP Receptor Dual Agonist HRS9531
GlobeNewswireJan 13 08:00 ET
Jiangsu Hengrui Medicine Gets Drug Registration for Cardiovascular Drug
MT NewswiresJan 12 22:39 ET
Chinese Drug Regulator Accepts Hengrui Medicine's Marketing Application for SHR4640 Tablets
MT NewswiresJan 9 23:31 ET
Express News | Hengrui Pharmaceuticals Says Application for H-Share Issuance and Listing Submitted to Hong Kong Stock Exchange
ReutersJan 6 10:10 ET

Comments

Moomoo AI

Mar 1, 2024 17:44

The decline in EPS has likely disappointed the market, making investors hesitant to buy. Despite the recent share price increase, the long-term performance has been less impressive, significantly under-performing the market.

Shareholders in Jiangsu Hengrui Medicine (SHSE:600276) Are in the Red If They Invested Three Years Ago

Moomoo AI

Feb 12, 2024 18:50

Jiangsu Hengrui Medicine's high P/E ratio is backed by its promising earnings outlook. Investors retain the stock, expecting a bright future. The risk of earnings decline is not seen as substantial enough to justify a lower P/E ratio, bolstering the share price.